Document:

EX-10.7

 Exhibit 10.7 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

Amendment No 1 
 to the License
and Collaboration Agreement of 19th May 2015 
 by and between 

BioNTech AG 
 and 

Genmab A/S 

 This Amendment No 1 is made the 18th day of May 2017
(the “Amendment No 1 Effective Date”), by and between 
 GENMAB A/S, a Danish corporation having its principal Office at Bredgade 34E, 1260
Copenhagen K, Denmark, CVR no. 2102 3884 (“Genmab”), and 
 BIONTECH AG, a German corporation having its principal office at An der Goldgrube 12,
55131 Mainz, Germany (“BioNTech”) 
 (Genmab and BioNTech are sometimes hereinafter referred to collectively as the “Parties” or
individually as a “Party”) 
 RECITALS: 
  

	 	A.	 Genmab and BioNTech entered into a License and Collaboration Agreement on 19 May 2015 to jointly research,
develop and commercialize polypeptide-based bispecific antibodies using Genmab’s proprietary DuoBody® Platform technology against certain target combinations in combination with
Genmab’s proprietary [***] Technology for the treatment of cancer (“the Agreement”); 

  

	 	B.	 Genmab and BioNTech entered into a Side Letter on 8 January 2016 regarding New Collaboration IP; and

  

	 	C.	 Genmab and BioNTech entered into a Side Letter No 2 on 13 May 2016 to include Genmab B.V.’s [***]
Technology in Phase A of the collaboration to investigate the applicability of this technology and combination of this technology with the Inert Format Technology and/or DuoBody Platform technology with respect to certain Collaboration Targets
expressed on the same cell (the cis concept);  

 NOW, THEREFORE, in consideration of the premises and the mutual covenants
and agreements herein contained, and for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree to amend the Agreement as follows: 

1. Except as otherwise defined herein, the words and phrases in the Agreement shall have the same meaning in this Amendment No 1. 

2. Section 2.5 of the Agreement is deleted in its entirety and replaced by the below new Section 2.5 with retroactive effect from the Effective
Date:  
 “2.5 Duration of Phase A. The joint research and development activities in Phase A are
scheduled for an initial term of [***] years starting on the Effective Date. The Parties shall discuss in good faith an extension of Phase A at the latest [***] months before the end of the initial term, provided that any extension of Phase A shall
require the written mutual agreement between the Parties.” 

 3. The Research Plan is hereby amended by adding the below additional research activities: 

For the trans product concepts, additional in vivo POC, in vitro immunogenicity screening and in vitro MoA studies will be performed to
support clinical candidate nomination. 
 For the tumor targeting approach, additional in vitro and in vivo POC experiments will be performed
for [***] support selection of preferred target and antibody combinations. In case POC is established, selected clone(s) will be humanized and tested in in vivo models and exploratory toxicity studies. 

The Joint Research Committee (JRC) shall decide and document: 
  

	 	•	 	 the specific details of the agreed additional research activities to be performed 

 

	 	•	 	 the budget for the additional research activities 

 

	 	•	 	 the allocation of FTEs for the additional research activities, 

 

	 	•	 	 the relevant criteria to be met for establishing POC, and 

 

	 	•	 	 the relevant specifications to be met for nominating a Clinical Candidate 

4. Save as set forth in this Amendment No 1, all other terms and conditions of the Agreement shall remain in full force and effect. 

5. This Amendment No 1 may be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single
instrument, and all such counterparts together shall be deemed an original of this Amendment No 1. 
 IN WITNESS WHEREOF, authorized representatives of the
Parties have duly executed this Amendment No 1 as of the Amendment No 1 Effective Date. 
  

									
	For GENMAB A/S:	 		 	For BIONTECH AG:
					
	By:	 	 [***]
	 		 	By:	 	 [***]

					
	Name:	 	 [***]
	 		 	Name:	 	 [***]

					
	Title:	 	 [***]
	 		 	Title:	 	 [***]EX-10.8

 Exhibit 10.8 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

AMENDMENT No 2 
 to

 the License and Collaboration Agreement of 19th May 2015 

by and between 
 BioNTech AG 

and 
 Genmab A/S 

  
 1 

 This Amendment No 2 is made and entered into as of [###] (Amendment No 2 Effective Date) by and between
BioNTech AG, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (Biontech) and Genmab A/S, CVR no. 21023884, a Danish corporation having its principal office at Bredgade 34E,
DK-1260 Copenhagen K, Denmark, (Genmab) (Biontech and Genmab each a Party and together the Parties). 
 PREAMBLE

 WHEREAS, Biontech and Genmab are parties to a certain License and Collaboration Agreement of 19th May 2015 by and between BioNTech AG and
Genmab A/S, as amended by the Amendment No 1 dated May 18, 2017 (the “Agreement”) as well as a Side Letter dated January 8, 2016 and a Side Letter No 2 dated May 13, 2016
(as amended by the Amendment No 1 to Side Letter No 2 dated May 19, 2017; 
 WHEREAS, Biontech and Genmab wish to include Genmab’s
proprietary [***] antibody panel (the “[***] Antibodies”) in the collaboration, and the Parties may want to include further proprietary antibody panels in the collaboration in the future upon prior written mutual agreement; 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties, intending to be legally bound, hereby
agree to amend the Agreement as follows: 
  

	 	1.	 Except as otherwise defined herein, the words and phrases in the Agreement shall have the same meaning as in
this Amendment No 2. 

  

	 	2.	 New Exhibit 8 as attached to this Amendment No 2 shall be included as an integral part of the Agreement.

  

	 	3.	 Section 1.29 is hereby deleted and restated in its entirety as follows: 

“1.29    Collaboration Targets means the following antigens: [***] (also
known as [***] (also known as [***] and [***]. Further Collaboration Targets may be added through written amendment of the Research Plan.” 
  

	 	4.	 The following new Section 1.49A shall be inserted immediately after Section 1.49:

 “1.49A    [***] Tumor Targeting Product Concept means
any one of the product concepts listed below: 
 [***] 
  

	 	5.	 Section 1.64 is hereby deleted and restated in its entirety as follows: 

  
 2 

 “Genmab Antibodies    means the [***]
Antibodies and [***] Antibodies as well as further Antibodies proprietary to Genmab that may be included in the collaboration and listed in the Research Plan upon prior written mutual agreement.” 

 

	 	6.	 The following new Section 1.97A shall be inserted immediately after Section 1.97:

 “1.97A    [***] Agreement means the Amended
and Restated Evaluation and Commercialization Agreement, entered into as of July 12, 2012, but effective as of February 25, 1999 by and between [***] and Genmab A/S for using [***] for generating and developing antibodies for treatment of
humans. A redacted copy of the [***] Agreement shall be provided to Biontech upon request.” 
  

	 	7.	 The following new Section 1.101A shall be inserted immediately after Section 1.101:

 “1.101A    [***] Agreement means the Platform License
Agreement entered into by Genmab A/S, Genmab B.V. and [***] (“[***]”), dated October 1, 2014 for the development and commercialization of products generated by Genmab A/S and/or Genmab B.V. using the [***] Technology (as that term is
defined in the [***] Agreement). A summary of the financial terms for the development and commercialization of products generated under this [***] Agreement is set forth in Exhibit 8. A redacted copy of the [***] Agreement shall be provided
to Biontech upon request.” 
  

	 	8.	 The following new Sections 1.108A and 1.108B shall be inserted immediately after Section 1.108:

 “1.108A    [***] Antibodies means the 39 Antibodies against [***]
proprietary to Genmab, which have been generated by Genmab using the [***] technology pursuant to the [***] Agreement.” 

“1.108B [***] Tumor Targeting Product Concept means any one of the product concepts listed below: 

[***] 
 For the avoidance of doubt, the term
[***] Tumor Targeting Product Concept shall also include abovementioned product concepts whose mode-of-action may rely, in whole or in part, on
transactivation of T cells and antigen-presenting cells, or, as the case may be, on any other mode-of-action as may be revealed by future preclinical and/or clinical
research. 
  

	 	9.	 The following new Section 1.140 shall be inserted immediately after Section 1.139:

  
 3 

 “1.140    [***] Antibodies
means the [***] Antibodies against [***] proprietary to Genmab, which have been generated by Genmab using [***] transgenic mouse technology pursuant to the [***] Agreement.” 

 

	 	10.	 The following new Sections 7.1A-7.1E shall be inserted immediately
after Section 7.1: 

 “7.1A Upfront payment by [***] for use of [***]
Antibodies 
 [***] shall pay to [***] the following non-refundable payments on a
Collaboration Product-by-Collaboration Product or [***] Unilateral Product-by-[***] Unilateral Product basis incorporating a
[***] Antibody in a [***] Tumor Targeting Product Concept: 
 a. [***] within [***] following the date on which the Joint Research Committee
for the first time and in accordance with Section 2.10 (as documented by the minutes of the Joint Research Committee) selects a Preferred Clinical Candidate which incorporates a Genmab Antibody in a Tumor Targeting Product Concept; and such
Preferred Clinical Candidate is either (i) advanced to a Collaboration Product pursuant to Section 2.10 or (ii) a [***] Unilateral Product pursuant to Section 2.11; 

b. [***] within [***] following the date on which (i) the Joint Steering Committee determines that there is
Freedom-to-Operate for the [***] Antibody included in the Collaboration Product in accordance with the criteria set forth and agreed by the Joint IP Committee or (ii)
[***] determines that there is Freedom-to-Operate for the [***] Antibody included in the Unilateral Product in accordance with the criteria set forth and agreed by the
Joint IP Committee. The criteria shall stipulate that there shall be Freedom-to-Operate provided no claims of a patent issued in the [***] or [***] expiring after [***]
disclose the [***] Antibody included in the Collaboration Product or Unilateral Product or use thereof for the treatment of cancer indications contemplated for the Collaboration Product or Unilateral Product as reflected in the applicable
development plan, and provided no [***] application, [***] application or [***] application exists expiring after [***] with narrow and concrete claims covering the Genmab Antibody included in the Collaboration Product or Unilateral Product or use
thereof for the treatment of cancer indications contemplated for the Collaboration Product or Unilateral Product as reflected in the applicable development plan. Further criteria may be defined and agreed by the Joint IP Committee in connection with
the Selection of a Clinical Candidate. The Freedom-to-Operate determination shall be made prior to the filing of an IND. Should Biontech determine that there is not Freedom-to-Operate with respect to a Unilateral Product it shall provide Genmab with written evidence in support of that finding under a joint defense agreement to be entered
into by the Parties. 

  
 4 

 For the avoidance of doubt, the payment under Section 7.1A.a and Section 7.1A.b
shall not be considered a milestone payment, and shall not become due or payable upon the achievement of any other milestones set forth in this Agreement, but only upon occurrence of the events set forth in this Section 7.1A.a or
Section 7.1A.b. 
 7.1B Payment by [***] for use of [***] Antibodies 

[***] shall pay to [***] the following non-refundable payment on a Collaboration Product-by-Collaboration Product or [***] Unilateral Product-by-[***] Unilateral Product basis incorporating a [***] Antibody in a
[***] Tumor Targeting Product Concept: 
 [***] within [***] following the dosing of the [***] patient in the first Phase I Clinical Trial
(or the first part of a Phase I/II Clinical Trial) for the [***] Indication. 
 This payment shall be in addition to any payments due for a
Unilateral Product as set forth in Exhibit 1. 
 For the avoidance of doubt, the payment under Section 7.1B shall not be considered a
milestone payment, and shall not become due or payable upon the achievement of any other milestones set forth in this Agreement, but only upon occurrence of the events set forth in this Section 7.1B. 

7.1C Upfront payment by [***] for use of [***] Antibodies in a Tumor Targeting Product Concept 

[***] shall pay to [***] the following non-refundable payments on a Collaboration Product-by-Collaboration or [***] Unilateral Product-by [***] Unilateral Product basis incorporating an [***] Antibody in a Tumor
Targeting Product Concept: 
 a. [***] within [***] following the date on which the Joint Research Committee for the first time and in
accordance with Section 2.10 (as documented by the minutes of the Joint Research Committee) selects a Preferred Clinical Candidate which incorporates an [***] Antibody in an [***] Tumor Targeting Product Concept; and such Preferred Clinical
Candidate is either (i) advanced to a Collaboration Product pursuant to Section 2.10 or (ii) a [***] Unilateral Product pursuant to Section 2.11; 

b. [***] within [***] following the date on which (i) the Joint Steering Committee determines that there is
Freedom-to-Operate for the [***] Antibody included in the Collaboration Product in accordance with the criteria set forth and agreed by the Joint IP Committee or
(ii) Genmab 

  
 5 

 
determines that there is Freedom-to-Operate for the [***] Antibody included in the Unilateral Product in accordance
with the criteria set forth and agreed by the Joint IP Committee. The criteria shall stipulate that there shall be Freedom-to-Operate provided no claims of a patent
issued in the [***] or [***] expiring after [***] disclose the [***] Antibody included in the Collaboration Product or Unilateral Product or use thereof for the treatment of cancer indications contemplated for the Collaboration Product or Unilateral
Product as reflected in the applicable development plan, and provided no [***] application, [***] application or [***] application exists expiring after [***] with narrow and concrete claims covering the [***] Antibody included in the Collaboration
Product or Unilateral Product or use thereof for the treatment of cancer indications contemplated for the Collaboration Product or Unilateral Product as reflected in the applicable development plan, and provided no [***] application, [***]
application or [***] application exists expiring after [***] with narrow and concrete claims covering the [***] Antibody included in the Collaboration Product or Unilateral Product as reflected in the applicable development plan. Further criteria
may be defined and agreed by the Joint IP Committee in connection with the Selection of a Clinical Candidate. The Freedom-to-Operate determination shall be made prior to
the filing of an IND. Should Genmab determine that there is not Freedom-to-Operate with respect to a Unilateral Product it shall provide Biontech with written evidence
in support of that finding under a joint defense agreement to be entered into by the Parties. 
 For the avoidance of doubt, the payment
under Section 7.1C.a and Section 7.1C.b shall not be considered a milestone payment, and shall not become due or payable upon the achievement of any other milestones set forth in this Agreement, but only upon occurrence of the events set
forth in this Section 7.1C.a or Section 7.1C.b. 
 7.1D Payment by [***] for use of [***]
Antibodies in [***] Tumor Targeting Product Concept 
 [***] shall pay to [***] the following non-refundable payment on a Collaboration Product-by-Collaboration Product or [***] Unilateral
Product-by-[***] Unilateral Product basis incorporating an [***] Antibody in an [***] Tumor Targeting Product Concept: 

[***] within [***] weeks following the dosing of the first patient in the first Phase I Clinical Trial (or the first part of a Phase I/II
Clinical Trial) for the first Indication. 
 This payment shall be in addition to any payments due for a Unilateral Product as set forth in
Exhibit 1. 

  
 6 

 For the avoidance of doubt, the payment under Section 7.1D shall not be considered a
milestone payment, and shall not become due or payable upon the achievement of any other milestones set forth in this Agreement, but only upon occurrence of the events set forth in this Section 7.1D. 

For the avoidance of doubt, if a Collaboration Product becomes a Unilateral Product, the payments already made for the Collaboration Product
pursuant to Sections 7.1A-7.1D, as applicable, shall be deemed paid for the Unilateral Product and shall not become payable again. 

7.1E Future Collaboration Products or Unilateral Products using additional proprietary antibodies 

In case the Parties decide, by prior written agreement, to include further Antibodies proprietary to either of the Parties in the
collaboration, the principles outlined in Sections 7.1A-7.1D and Section 9.1j shall apply with respect to such proprietary Antibodies, and the Agreement shall be amended accordingly to reflect this. For
the avoidance of doubt, if any such further proprietary Antibodies are to be used in combination with an [***] Antibody, a [***] Antibody or a [***] Antibody, payments are still due for the use of an [***] Antibody, a [***] Antibody or a [***] F
Antibody in accordance with the principles outlined in Sections 7.1A-7.1D.” 
  

	 	11.	 New Section 9.1j shall be inserted immediately after Section 9.1i: 

“j. The Parties agree, with respect to any joint patent filings on any Collaboration Product or Unilateral Product incorporating a [***]
Antibody in an [***] Tumor Targeting Product Concept or an [***] Antibody in an [***] Tumor Targeting Product Concept, that the Parties shall only be allowed to specifically disclose the Preferred Clinical Candidate and one (1) Back-up Candidate, if applicable, in such joint patent filings, unless the Parties mutually agree that further Bispecific Antibodies may be included.“ 

 

	 	12.	 New Sections 10.A, 10.B and 10.C shall be inserted immediately after Section 10: 

“10A. [***] Antibodies    The Parties acknowledge that the use of any [***] Antibodies in
a Collaboration Product or Unilateral Product shall be subject to the terms and conditions of the [***] Agreement, including the financial terms as outlined in Exhibit 8. The Parties shall share the payments pursuant to the [***] Agreement
[***] in case of a Collaboration Product. [***] shall be solely responsible for the payments pursuant to the [***] Agreement with respect to a [***] Unilateral Product, and [***] shall be solely responsible for the payments pursuant to the [***]
Agreement with respect to a [***] Unilateral Product, and shall reimburse [***] for all payments due under the [***] Agreement for such Biontech Unilateral Product. Genmab hereby grants to Biontech a sublicence under its rights under the [***]
Agreement for the [***] Antibodies it being understood that Sections 9.3, 14.7c and 14.7d of this Agreement shall apply mutatis mutandis to this sublicense, except that the payment structure with respect to the [***] Agreement shall be as set
forth in this Section 10.A.” 

  
 7 

 10B. [***] Antibodies The Parties acknowledge that the use of
any [***] Antibodies in a Collaboration Product or Unilateral Product shall be subject to the terms and conditions of the [***] Agreement. [***] is an [***] (as that term is defined in the [***] Agreement). Genmab hereby grants to Biontech a
sublicense under its rights under the [***] Agreement for the [***] Antibodies it being understood that Sections 9.3, 14.7c and 14.7d of this Agreement shall apply mutatis mutandis to this sublicense. 

10C. [***] Antibodies Biontech declares that the use of any [***] Antibodies in a Collaboration Product or
Unilateral Product are not subject to any special terms or conditions of an underlying agreement.” 
  

	 	13.	 Save as set forth in this Amendment No 2, all other terms and conditions of the Agreement shall remain in full
force and effect. 

  

	 	14.	 This Amendment No 2 may be signed in any number of counterparts with the same effect as if the signatures
to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of the Amendment No 2. 

[REST OF PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this
Amendment No 2 as of the Amendment No 2 Effective Date. 
  

									
	For BioNTech AG:	  	    	  	Genmab A/S
			
	Date: AUGUST 4, 2017	  		  	Date: 4 AUGUST 2017
	Signature:	  	_____[***]________________	  		  	Signature:	  	____[***]_________________
					
	Print name:	  	____[***]_________________	  		  	Print name:	  	_____[***]________________
					
	Title:	  	______[***]_______________	  		  	Title:	  	_____[***]________________

  
 9 

 Exhibit 8: [***] 

[***] 

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]